Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05703607 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 484
- Enrollment target
NCT05703607 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 484 participants.
The verdict
NCT05703607, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 484 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune system's reaction) of the study vaccine called Varicella Zoster Virus modRNA (VZV modRNA). We are seeking for healthy participants 50 through 85 years of age. This study will be conducted in 2 substudies: Substudy A (Phase 1) and Substudy B (Phase 2). Substudy A: This substudy is the Phase 1 portion of the study. In this substudy, participants will receive 1 of 3 VZV modRNA vaccine candidates (different construct, different dose levels and different formulation \[frozen or freeze dry powder\]) or the approved shingles vaccine intramuscularly. Participants will be assigned in 1 of 10 groups in the study. Vaccination will be given either as a 2-dose series using one of two dosing schedules (either 2-months apart or 6-months apart), or (in one of the groups), as a single VZV modRNA vaccine at the first vaccination visit and saline at the second vaccination visit. Participants will take part in this study for 8 to 12 months depending on the group they are assigned to. Some group(s) will continue into persistence-of-immunity (overtime assessment of effect of vaccine) portion of the study. Those participants assigned to these selected groups will be involved in the study for up to 5 years. Substudy B: This substudy is the Phase 2 portion of the study. In this part of the study, participants will receive either VZV modRNA vaccine at selected dose level/schedule/formulation or approved shingles vaccine. This selection was determined from data collected in Substudy A. Participants will be involved in this study for up to 5 years.
Interventions
- BIOLOGICAL Shingrix
- BIOLOGICAL Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection
- BIOLOGICAL Candidate 1: PF-07915234: VZV modRNA Suspension for Injection
- BIOLOGICAL Candidate 2: PF-07921188: VZV modRNA Suspension for Injection
- BIOLOGICAL Candidate 3: PF-07921186: VZV modRNA Suspension for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 484 participants |
| Start Date | 2023-01-25 |
| Est. Completion | 2025-09-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05703607
The ClinicalTrials.gov registry entry for NCT05703607 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 484 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Shingrix is the first listed.
NCT05703607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05703607 about?
NCT05703607 is a clinical study titled "A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults". The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune system's reaction) of the study vaccine called Varicella Zoster Virus modRNA (VZV modRNA). We are seeking for healthy participants 50 through 85 years o...
What is the current status of trial NCT05703607?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 484 participants. The study started on 2023-01-25. Estimated completion is 2025-09-23.
What interventions are being tested in trial NCT05703607?
The interventions under investigation include: Shingrix (BIOLOGICAL), Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection (BIOLOGICAL), Candidate 1: PF-07915234: VZV modRNA Suspension for Injection (BIOLOGICAL), Candidate 2: PF-07921188: VZV modRNA Suspension for Injection (BIOLOGICAL), Candidate 3: PF-07921186: VZV modRNA Suspension for Injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT05703607?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.